Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis
Marjan Farid,Brandon D Ayres,Eric Donnenfeld,Ian Benjamin Gaddie,Preeya K Gupta,Edward Holland,Richard Lindstrom,Stephen C Pflugfelder,Paul M Karpecki,Kelly K Nichols,Christopher E Starr,Elizabeth Yeu
DOI: https://doi.org/10.2147/OPTH.S399989
2023-02-28
Clinical Ophthalmology
Abstract:Marjan Farid, 1 Brandon D Ayres, 2 Eric Donnenfeld, 3 Ian Benjamin Gaddie, 4 Preeya K Gupta, 5 Edward Holland, 6 Richard Lindstrom, 7 Stephen C Pflugfelder, 8 Paul M Karpecki, 9 Kelly K Nichols, 10 Christopher E Starr, 11 Elizabeth Yeu 12 1 Gavin Herbert Eye Institute, UC-Irvine, Irvine, CA, USA; 2 Wills Eye Hospital, Philadelphia, PA, USA; 3 Ophthalmic Consultants of Long Island, Long Island, NY, USA; 4 Gaddie Eye Centers, Louisville, KY, USA; 5 Triangle Eye Consultants, Raleigh, NC and Tulane University, New Orleans, LA, USA; 6 University of Cincinnati, Cincinnati, OH, USA; 7 University of Minnesota, Minneapolis, MN, USA; 8 Baylor College of Medicine, Houston, TX, USA; 9 Kentucky Eye Institute, Lexington, KY, USA; 10 University of Alabama at Birmingham, School of Optometry, Birmingham, AL, USA; 11 Weill Cornell Medicine, New York, NY, USA; 12 Virginia Eye Consultants, Norfolk, VA, USA Correspondence: Marjan Farid, University of California, 850 Health Sciences Road, Mail Code: 4375, Irvine, CA, 92697, USA, Tel +1 949 824-0327, Email Purpose: To obtain consensus on Demodex blepharitis (DB) treatment using a modified Delphi panel process. Methods: Literature search identified gaps in knowledge surrounding treatment of DB. Twelve ocular surface disease experts comprised the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH). They completed a live roundtable discussion in addition to 3 surveys consisting of scaled, open-ended, true/false, and multiple-choice questions pertaining to the treatment of DB. Consensus for scaled questions using a 1 to 9 Likert scale was predefined as median scores of 7– 9 and 1– 3. For other question types, consensus was achieved when 8 of 12 panelists agreed. Results: The experts agreed that an effective therapeutic agent for treatment of DB would likely decrease the necessity of mechanical intervention, such as lid scrubs or blepharoexfoliation (Median = 8.5; Range 2– 9). When treating DB, panelists believed that collarettes serve as a surrogate for mites, and that eliminating or reducing collarettes should be the main clinical goal of treatment (Median = 8; Range 7– 9). The panelists would treat patients with at least 10 collarettes, regardless of other signs or symptoms and agreed that DB can be cured, but there is always the possibility for a reinfestation (n = 12). There was also consensus that collarettes, and therefore mites, are the primary treatment target and the way by which clinicians can monitor patient response to therapy (Median = 8; Range 7– 9). Conclusion: Expert panelists achieved consensus on key facets of DB treatment. Specifically, there was consensus that collarettes are pathognomonic for DB, that DB patients with > 10 collarettes should be treated even in the absence of symptoms, and that treatment efficacy can be tracked by collarette resolution. By increasing awareness about DB, understanding the goals of and monitoring treatment efficacy, patients will receive better care and, ultimately, better clinical outcomes. Keywords: collarettes, cylindrical dandruff, ocular surface disease, eyelid disease Lid and ocular surface diseases often share a constellation of signs, including lid margin erythema, meibomian gland inspissation, conjunctivitis, conjunctival erythema, tear film instability, and keratitis. Blepharitis is a common inflammatory ocular disease that affects the eyelid margin, frequently resulting in disruption of the ocular surface and tear film. 1 When present, blepharitis can damage the ocular surface and exacerbate concurrent ocular surface disorders. 1–3 Because of its chronic nature and frequent comorbidity with other ocular surface diseases, managing these patients can be difficult. 2 There are no FDA-approved treatments specifically for blepharitis, so the goal is often palliative, providing short-term management of signs and symptoms, with strategies such as warm compresses and lid hygiene, topical anti-inflammatory agents, and topical and oral antibiotics. 2 While these options may temporarily relieve patient symptoms, they rarely address the root cause of the disease. One of the most common etiologies of blepharitis is known to be Demodex infestation, representing up to 70% of all patients diagnosed with blepharitis. 4–9 Demodex is a microscopic parasite commonly found on the human body. 5,10 There are more than 1600 species of Demodex mites, with Demodex folliculorum (Figure 1) prevalent in th -Abstract Truncated-